Clinical Trial Update: Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating tucidinostat in combination with nab-paclitaxel for advanced HR+/HER2- breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hr-positive Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Tucidinostat (tucidinostat)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: HR+/HER2- Breast Cancer | Phase 2 | Status: UNKNOWN